Loading...
Prime Medicine, Inc.
PRME•NASDAQ
HealthcareBiotechnology
$1.69
$0.33(24.26%)
Prime Medicine, Inc. (PRME) Financial Performance & Statements
Review Prime Medicine, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
-5.84%
↓ 5.84%
Net Income Growth
1.14%
↑ 1.14%
Operating Cash Flow Growth
25.72%
↑ 25.72%
Operating Margin
-496.20%
↓ 496.20%
Gross Margin
95.87%
↑ 95.87%
Net Profit Margin
-485.37%
↓ 485.37%
ROE
-125.05%
↓ 125.05%
ROIC
-70.27%
↓ 70.27%
Prime Medicine, Inc. (PRME) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Prime Medicine, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.18M | $209000.00 | $37.77M | $591000.00 |
| Cost of Revenue | $1.72M | $0.00 | $0.00 | $0.00 |
| Gross Profit | $466000.00 | $209000.00 | $37.77M | $0.00 |
| Gross Profit Ratio | $0.21 | $1.00 | $1.00 | $0.00 |
| R&D Expenses | $34.10M | $40.34M | $43.07M | $37.77M |
| SG&A Expenses | $12.30M | $14.10M | $12.60M | $11.16M |
| Operating Expenses | $46.41M | $54.44M | $55.67M | $48.93M |
| Total Costs & Expenses | $46.41M | $54.44M | $55.67M | $48.93M |
| Interest Income | $1.54M | $697000.00 | $611000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.72M | $1.56M | $1.54M | $1.31M |
| EBITDA | -$42.51M | -$52.67M | -$54.13M | -$47.03M |
| EBITDA Ratio | -$19.47 | -$252.03 | -$1.43 | -$79.57 |
| Operating Income | -$44.22M | -$54.23M | -$55.67M | -$48.34M |
| Operating Income Ratio | -$20.26 | -$259.48 | -$1.47 | -$81.80 |
| Other Income/Expenses (Net) | $1.95M | $1.71M | $211000.00 | $2.71M |
| Income Before Tax | -$42.28M | -$52.52M | -$55.46M | -$45.63M |
| Income Before Tax Ratio | -$19.37 | -$251.28 | -$1.47 | -$77.20 |
| Income Tax Expense | $0.00 | $0.00 | -$134000.00 | $134000.00 |
| Net Income | -$42.28M | -$52.52M | -$55.33M | -$45.76M |
| Net Income Ratio | -$19.37 | -$251.28 | -$1.46 | -$77.43 |
| EPS | -$0.35 | -$0.44 | -$0.46 | -$0.44 |
| Diluted EPS | -$0.35 | -$0.44 | -$0.46 | -$0.44 |
| Weighted Avg Shares Outstanding | $118.60M | $119.76M | $119.19M | $104.47M |
| Weighted Avg Shares Outstanding (Diluted) | $118.60M | $119.76M | $119.19M | $104.47M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan